Clinical Trial Update: An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 [Phase 3]

View source ↗

Summary

This document reports the completion of an open-label Phase 3 study for non-responders to VRDN-001-101 and VRDN-001-301 in Thyroid Eye Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-001

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED